US3223484A - Diagnostic procedure - Google Patents

Diagnostic procedure Download PDF

Info

Publication number
US3223484A
US3223484A US88676A US8867661A US3223484A US 3223484 A US3223484 A US 3223484A US 88676 A US88676 A US 88676A US 8867661 A US8867661 A US 8867661A US 3223484 A US3223484 A US 3223484A
Authority
US
United States
Prior art keywords
beta
lipoprotein
serum
blood
antiserum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US88676A
Inventor
Fisk Roy Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cooper Laboratories Inc
Hyland Laboratories Inc
Original Assignee
Hyland Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hyland Laboratories Inc filed Critical Hyland Laboratories Inc
Priority to US88676A priority Critical patent/US3223484A/en
Application granted granted Critical
Publication of US3223484A publication Critical patent/US3223484A/en
Assigned to COOPER LABORATORES, INC. reassignment COOPER LABORATORES, INC. ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: BAXTER TRAVENOL LABORATORIES, INC., A CORP. OF DE
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N31/00—Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroup; Apparatus specially adapted for such methods
    • G01N31/02—Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroup; Apparatus specially adapted for such methods using precipitation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/815—Test for named compound or class of compounds

Definitions

  • the present invention relates to diagnostic procedures for determining the presence of abnormal or pathological states or conditions. More particularly it relates to novel diagnostic procedures and reagents for the determination of the amount of serum lipids in blood.
  • beta-lipoprotein antiserum employed in the practice of the present invention, it is desirable that the immunizing beta-lipoprotein be immunologically free of other antigenic material such as albumin and gamma globulin, the most common contaminates.
  • beta-lipoprotein is obtained by conventional ultracentrifugation procedures at an appropriate density, time and speed.
  • the beta-lipoprotein thus obtained can be rendered immunologically free of possible albumin and gamma globulin contaminants by absorbing these contaminants, if present, on appropriate antiserum.
  • this beta-lipoprotein is injected into a suitable animal using conventional immunological techniques, the animal will respond by producing anti-serum which is specific only to the beta-lipoprotein.
  • a beta-lipoprotein antiserum is prepared by conventional techniques in a suitable animal (e.g. rabbit, sheep, goat or horse) and combined with the human serum to be tested.
  • the antiserum should be capable of precipitating all of the beta-lipoprotein in human serums having from 300 to 1500 mg. of beta-lipoprotein per 100 ml. of blood serum.
  • the betalipoprotein immunocrit is then determined by the following formula:
  • Betalipoprotein immunocrit The value thus obtained is then compared to the immunocrit of a normal human being of the same sex, within the same age group.
  • the length of the column of precipitate can be translated directly into a serum beta-lipoprotein value by reference to a control standard.
  • This control standard is prepared by assaying by difiering techniques (eg analytical ultracentrifugation, polyanion precipitation or paper electrophoresis and the method of this invention) a number of serum samples having different levels of beta-lipoprotein and by relating the amounts of beta-lipoprotein as determined by direct assay of the beta-lipoprotein to the column heights of precipitate resulting from the practice of this invention.
  • beta-lipoprotein fraction was administered to rabbits via an initial intramuscular injection of the material in Freunds adjuvant. Subsequent subcutaneous injections were given at 4 week intervals, 7 days before each bleeding. The injections were continued until the beta-lipoprotein precipitin titer was such that two volumes of undiluted serum would precipitate all of the beta-lipoprotein in one volume of each of a number of human serums ranging over the normal and the abnormally high and low beta-lipoprotein levels which could be expected to be encountered in routine diagnosis, i.e. from 300 to 1500 mg. of beta-lipoprotein per 100 ml. of serum.
  • the sera from interval bleedings of rabbits with high precipitin titers were pooled and analyzed by immunoelectrophoresis for precipitin content.
  • One pool contained a significant amount of both albumin and gamma globulin precipitins, which were selectively absorbed with Cohn fractions II and V.
  • Other pools were contaminated with only albumin precipitins which were removed by absorption with Cohn fraction V.
  • the resultant absorbed antiserum pools gave one intense line in the characteristic beta-lipoprotein area upon immunoelectrophoresis against a pool of normal human sera.
  • the capillary tubes were centrifuged in a micro-hematocrit centrifuge for 10 minutes. The length of the resultant column of precipitate was measured with a low power microscope and eyepiece micrometer and found to be three mm. Reference to a control standard prepared for capillary tubes having these dimensions and for this column height of fluid indicated that the human test serum contained 900 mg. of beta-lipoprotein per 100 ml. of serum.
  • the beta-lipoprotein immunocrit by calculation, was found to be 5.
  • the human test serum of this invention was assayed .by the more complex, expensive and time-consuming polyanion precipitation and paper electrophoretic methods, and a close correlation was obtained.
  • the polyanion precipitation and the paper electrophoretic methods gave values of 875 and 910 mg. of beta-lipoprotein per 100 ml. of serum, respec- 'tively.
  • the method of determining the amount of beta-lipopro tein present in serum which comprises adding to said serum a beta-lipoprotein antiserum which is capable of precipitating all of the beta-lipoprotein in human serums that contain from 300 to 1500 mg. of beta-lipoprotein per 100 ml, of blood serum, drawing the resultant mixture into a capillary tube for a prescribed distance, sealing said tube, centrifuging the capillary tube, measuring the length of the column of precipitate, and relating the height of the precipitate to a control standard.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Description

United States Patent 3,223,484 DIAGNOSTIC PROCEDURE Roy Thomas Fisk, Glendale, Califi, assignor to Hyland Laboratories No Drawing. Filed Feb. 13, 1961, Ser. No. 88,676 1 Claim. (Cl. 23230) The present invention relates to diagnostic procedures for determining the presence of abnormal or pathological states or conditions. More particularly it relates to novel diagnostic procedures and reagents for the determination of the amount of serum lipids in blood.
Recent ob'ervations that serum lipid abnormalities are associated with atherosclerotic disease has created considerable interest in the development of methods for the detection of these abnormalities. Cholesterol and the serum lipids, each cholesterol esters, phospholipids and tryglycerides, are present in the blood stream both independent of and in combination with proteins. When combined with proteins, these lipids are characterized as lipoproteins. The beta-lipoproteins are believed to play a significant role in the etiology of atherosclerosis. Additionally, there is a significant beta-lipoprotein imbalance associated with diabetic disease states, and beta-lipoprotein quantitation is a useful diagnostic tool for this pathology.
The methods which have heretofore been available for quantitatively measuring beta-lipoproteins are primarily dependent upon solubility differences, electrophoretic behavior, differential flotation during ultracentrifugation and specific immunochemical precipitation. All of these techniques have involved expensive and time consuming operations, and their use has required significantly large quantities of specimen material.
It is an object of the present invention to disclose novel diagnostic procedures and reagents which make possible a simple, quick, inexpensive quantitative determination of beta-lipoprotein in blood. It is a further object to provide means for determining the extent to which serum cholesterol is combined in the form of beta-lipoprotein.
It is another object to provide a beta-lipoprotein diagnostic reagent which requires the use of minute quantities of specimen, e.g. one drop of serum, and which, therefore, negates the necessity for withdrawal of blood by syringe.
The above and still further objects are obtained by the present invention which involves the immunological precipitation of beta-lipoprotein and the subsequent volumetric quantitation of the resultant precipitate.
In the preparation of the beta-lipoprotein antiserum employed in the practice of the present invention, it is desirable that the immunizing beta-lipoprotein be immunologically free of other antigenic material such as albumin and gamma globulin, the most common contaminates. To this end, beta-lipoprotein is obtained by conventional ultracentrifugation procedures at an appropriate density, time and speed. The beta-lipoprotein thus obtained can be rendered immunologically free of possible albumin and gamma globulin contaminants by absorbing these contaminants, if present, on appropriate antiserum. When this beta-lipoprotein is injected into a suitable animal using conventional immunological techniques, the animal will respond by producing anti-serum which is specific only to the beta-lipoprotein.
In the preferred practice of the present invention a beta-lipoprotein antiserum is prepared by conventional techniques in a suitable animal (e.g. rabbit, sheep, goat or horse) and combined with the human serum to be tested. The antiserum should be capable of precipitating all of the beta-lipoprotein in human serums having from 300 to 1500 mg. of beta-lipoprotein per 100 ml. of blood serum. Preferably, there will be present an excess of 3,223,484 Patented Dec. 14, 1965 antibody in order to assure complete precipitation of all of the beta-lipoprotein contained in the serum specimen.
This combination is thoroughly mixed, and the mixture is immediately drawn into a standard capillary tube. The end of the capillary tube is then sealed. The capillary tube and its contents are centrifuged for about 5 to 10 minutes. The length of the resultant column of precipitate is then measured as, for example, with a low power microscope and eyepiece micrometer. The length of the total fluid column is also measured. The betalipoprotein immunocrit is then determined by the following formula:
Betalipoprotein immunocrit The value thus obtained is then compared to the immunocrit of a normal human being of the same sex, within the same age group.
If measured capillary tubes are employed, so that the length of the column is a constant, the length of the column of precipitate can be translated directly into a serum beta-lipoprotein value by reference to a control standard. This control standard is prepared by assaying by difiering techniques (eg analytical ultracentrifugation, polyanion precipitation or paper electrophoresis and the method of this invention) a number of serum samples having different levels of beta-lipoprotein and by relating the amounts of beta-lipoprotein as determined by direct assay of the beta-lipoprotein to the column heights of precipitate resulting from the practice of this invention. a
The practice of the present invention is further illustrated by reference to the following example.
EXAMPLE Preparation of the antigen A pool of human sera was used for preparation of betalipoprotein with standard ultracentrifugal techniques. The serum specimen was adjusted to a density of 1.063 and centrifuged at 30,000 rpm. for 16 hours (5 ml. of serum plus 4 ml. saline, density 1.1310). The topmost layer was carefully removed and dialyzed against normal saline. Immunoelectrophoretic analysis indicated slight traces of albumin and gamma globulin.
Preparation of the antiserum The beta-lipoprotein fraction was administered to rabbits via an initial intramuscular injection of the material in Freunds adjuvant. Subsequent subcutaneous injections were given at 4 week intervals, 7 days before each bleeding. The injections were continued until the beta-lipoprotein precipitin titer was such that two volumes of undiluted serum would precipitate all of the beta-lipoprotein in one volume of each of a number of human serums ranging over the normal and the abnormally high and low beta-lipoprotein levels which could be expected to be encountered in routine diagnosis, i.e. from 300 to 1500 mg. of beta-lipoprotein per 100 ml. of serum. The sera from interval bleedings of rabbits with high precipitin titers were pooled and analyzed by immunoelectrophoresis for precipitin content. One pool contained a significant amount of both albumin and gamma globulin precipitins, which were selectively absorbed with Cohn fractions II and V. Other pools were contaminated with only albumin precipitins which were removed by absorption with Cohn fraction V. The resultant absorbed antiserum pools gave one intense line in the characteristic beta-lipoprotein area upon immunoelectrophoresis against a pool of normal human sera.
' Diagnostic test A small quantity of human test serum was drawn into a capillary tube (dia. 1.2-1.4 mm. length 75 mm.), held in the vertical position, and one drop of this serum was allowed to fall passively onto a clean glass plate. To this drop of serum was added two drops of the above described antiserum using a Pasteur pipette (length of capillary stem, 120 mm., mean terminal dia 0.82 mm.). The serum and antiserum were mixed with a wooden applicator stick, using a circular motion. The resultant mixture was immediately drawn to a column height of 60 mm. into a capillary tube described above) and the end sealed by a flame. After standing at room temperature for 15 minutes, the capillary tubes were centrifuged in a micro-hematocrit centrifuge for 10 minutes. The length of the resultant column of precipitate was measured with a low power microscope and eyepiece micrometer and found to be three mm. Reference to a control standard prepared for capillary tubes having these dimensions and for this column height of fluid indicated that the human test serum contained 900 mg. of beta-lipoprotein per 100 ml. of serum.
The beta-lipoprotein immunocrit, by calculation, was found to be 5. As a crosscheck the human test serum of this invention was assayed .by the more complex, expensive and time-consuming polyanion precipitation and paper electrophoretic methods, and a close correlation was obtained. The polyanion precipitation and the paper electrophoretic methods gave values of 875 and 910 mg. of beta-lipoprotein per 100 ml. of serum, respec- 'tively.
For the particular system of this example (e.g. for this size capillary tube, the amounts of serum and antiserum employed, and the column height of fluid in the capillary tube) there is essentially a linear relationship between the height of the precipitate column in the capillary tube and the quantity of beta-lipoprotein normally contained in human serum specimens. Over the range of 300 to 1500 mg. of beta-lipoprotein per 100 ml. of blood, 1 millimeter of precipitate, in this system, represents 300 mg. of beta-lipoprotein per 100 ml. of blood, this being the control standard for the system. That is, a precipitate column height of 2 mm. indicates that the sample specimen contained 600 mg. of beta-lipoprotein per 100 ml. of blood, a column height of 3 mm. represents 900 mg. of beta-lipoprotein, etc.
It is of course readily apparent that in the commercial embodiment of the present invention the preparation of the antigen and the antiserum, and the preparation of control standards will be done by a biological manufacturer, and the diagnostic test itself will be performed at the physicians oflice, the hospital or the clinic.
The practice of the present invention in addition to requiring minimal equipment, and technical skill allows for the determination of beta-lipoprotein levels while employing extremely small volumes of blood (0.1 ml.). This degree of sensitivity permits the obtention of test blood by realtively painless and simple means, e.g. a finger prick, instead of by the otherwise requisite relatively complex procedures, e.g. withdrawal of blood from a vein by syringe and needle. Also, if laboratory facilities are not immediately available, the blood can be drawn into a capillary tube which has been treated with a preservative, e.g. phenol. The tube would then be sealed at both ends and sent to the laboratory for analysis.
It will be likewise apparent that many'modifications and changes may be made without departing from the spirit and scope of the present invention.
The embodiments of the present invention in which an exclusive property or privilege is claimed, are as follows:
The method of determining the amount of beta-lipopro tein present in serum which comprises adding to said serum a beta-lipoprotein antiserum which is capable of precipitating all of the beta-lipoprotein in human serums that contain from 300 to 1500 mg. of beta-lipoprotein per 100 ml, of blood serum, drawing the resultant mixture into a capillary tube for a prescribed distance, sealing said tube, centrifuging the capillary tube, measuring the length of the column of precipitate, and relating the height of the precipitate to a control standard.
7 References Cited by the Examiner Modern Laboratory Appliances, Catalog 59, Fisher Scientific Co., p. 168.
Boyle: J. Lab. and Clin. Med., vol. 53, pp. 572-281.
Bernfield: J. Biol. Chem, vol. 226, MayJune 1957, pp. 51, 58, 59 and 63.
Baker et al.: Proc. Soc. Exptl Biol. and Med., vol. 82, January 1953, pp. 119-122.
Experimental Immunochemistry" (Kabot et al.), pub. by Thomas, 1948, pp. 3234 cited of interest.
MORRIS O. WOLK, Primary Examiner.
WILLIAM B. KNIGHT, JAMES H. TAYMAN, JR., Examiners.
US88676A 1961-02-13 1961-02-13 Diagnostic procedure Expired - Lifetime US3223484A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US88676A US3223484A (en) 1961-02-13 1961-02-13 Diagnostic procedure

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88676A US3223484A (en) 1961-02-13 1961-02-13 Diagnostic procedure

Publications (1)

Publication Number Publication Date
US3223484A true US3223484A (en) 1965-12-14

Family

ID=22212764

Family Applications (1)

Application Number Title Priority Date Filing Date
US88676A Expired - Lifetime US3223484A (en) 1961-02-13 1961-02-13 Diagnostic procedure

Country Status (1)

Country Link
US (1) US3223484A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3519400A (en) * 1967-01-25 1970-07-07 Atomic Energy Commission Method of centrifugal separation and recovery of chemical species utilizing a liquid medium
US3615232A (en) * 1970-02-05 1971-10-26 Research Corp Method and reagent for determining total cholesterol in blood serum
US3876376A (en) * 1974-05-09 1975-04-08 American Cyanamid Co Linear determination of hemolytic complement activity in undiluted serum

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3519400A (en) * 1967-01-25 1970-07-07 Atomic Energy Commission Method of centrifugal separation and recovery of chemical species utilizing a liquid medium
US3615232A (en) * 1970-02-05 1971-10-26 Research Corp Method and reagent for determining total cholesterol in blood serum
US3876376A (en) * 1974-05-09 1975-04-08 American Cyanamid Co Linear determination of hemolytic complement activity in undiluted serum

Similar Documents

Publication Publication Date Title
Albrink The microtitration of total fatty acids of serum, with notes on the estimation of triglycerides
Neeld Jr et al. Macro-and micromethods for the determination of serum vitamin A using trifluoroacetic acid
May et al. Procedures for immunochemical study of histamine release from leukocytes with small volume of blood
Dods et al. Glycosylated hemoglobin assay and oral glucose tolerance test compared for detection of diabetes mellitus.
Owens et al. 125I radioimmunoassay of delta-9-tetrahydrocannabinol in blood and plasma with a solid-phase second-antibody separation method.
WO1991017441A1 (en) Analyte determination in biological fluids in the presence of interfering substances
Kubasik et al. Effect of duration and temperature of storage on serum analyte stability: examination of 14 selected radioimmunoassay procedures.
Gill et al. An evaluation of a C-reactive protein assay using a rate immunonephelometric procedure
US4294818A (en) Methods and materials for detection of multiple sclerosis
Brooks et al. Rapid diagnosis of tuberculous meningitis by frequency-pulsed electron-capture gas-liquid chromatography detection of carboxylic acids in cerebrospinal fluid
Martınez-Subiela et al. Effects of haemolysis, lipaemia, bilirubinaemia and fibrinogen on protein electropherogram of canine samples analysed by capillary zone electrophoresis
Gordon et al. Specific and sensitive determination of fibrinogen-degradation products by radioimmunoassay
Noguchi Serum diagnosis of syphilis and luetin reaction
Magnani et al. A method for the quantitative determination of the abnormal lipoprotein (LP-X) of obstructive jaundice
KENT et al. Measurement of IgG in equine blood by immunoturbidimetry and latex agglutination
US3223484A (en) Diagnostic procedure
Gitlin et al. The quantitative estimation of serum albumin in human body fluids by direct titration with specific horse antiserum
Voss et al. Evaluation of capillary collection system for HbA1c specimens
CN104730231B (en) A kind of sample buffer for fluorescence immunoassay detection by quantitative and application thereof
Wu et al. Highly sensitive method for the assay of plasminogen
Cary et al. Abbott radiative energy attenuation method for quantifying ethanol evaluated and compared with gas-liquid chromatography and the Du Pont aca.
JPS6345066B2 (en)
Thurston et al. A rapid method for recovering serologically active globulins by sodium sulfate precipitation
Karsh et al. Quantitative determination of rheumatoid factor by an enzyme-labeled immunoassay
Brunfeldt et al. The antigenic properties of pig insulin

Legal Events

Date Code Title Description
AS Assignment

Owner name: COOPER LABORATORES, INC., 3145 PORTER DRIVE, PALO

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:BAXTER TRAVENOL LABORATORIES, INC., A CORP. OF DE;REEL/FRAME:004067/0785

Effective date: 19820917